Antroquinonol (Hocena), an anti-cancer and anti-hyperlipidemia drug developed by a Taiwanese firm as a potential medicine to treat COVID-19, was approved by Peru's authorities to begin phase II trials, according to its developer.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Direct Hualien-Incheon flights to be suspended at end of July
07/27/2026 02:51 PM - Business
Taiwan, U.K. sign MOU to boost bilateral drone industry exchanges
07/27/2026 02:43 PM - Politics
Japanese veteran lawmaker awarded honor for promoting bilateral ties
07/27/2026 02:25 PM - Business
Taiwan shares close down 0.05%
07/27/2026 01:44 PM - Society
Ko Wen-je's digital monitoring to switch to electronic bracelet
07/27/2026 01:25 PM